Table II.
Thromboembolic complications with the use of the PCC Confidex
| Author, year (reference) | Study design | Inclusion criteria | N. of patients | Thromboembolic events (%) |
|---|---|---|---|---|
| Evans, 2001 (37) | Prospective non-randomised | Major bleeding and INR > 14 | 10 | 0/10 |
| Preston, 2002 (38) | Prospective non-randomised | Major bleeding or need for urgent reversal of anticoagulation | 42 | 1/42 (2.4) |
| Lorenz, 2007 (39) | Prospective cohort | Need for urgent reversal of anticoagulation | 8 | 0/8 |
| Pabinger, 2008 (40) | Prospective multicentre | Emergency anticoagulation reversal | 43 | 1/43 (2.3) |
| Bruce, 2008 (41) | Retrospective analysis | Severe bleeding | 24 | 0/24 |
| Schick, 2008 (42) | Retrospective | Major bleeding or urgent anticoagulation reversal | 50 | 0/50 |
| Staudinger, 1999 (43) | Prospective | Overt bleeding or planned invasive procedures in critically ill patients | 16 | 0/16 |
| Lorenz, 2003 (44) | Prospective multicentre | Acute bleeding or surgical/invasive procedures in patients with liver disease | 22 | 0/22 |
| Total | 165 | 2/215 (0.9) |